Mazdutide is among the compounds studied in metabolic and weight-regulation research. Simultaneous activation of the GLP-1 and glucagon receptors: GLP-1-mediated appetite suppression and insulin release combined with glucagon-mediated increases in energy expenditure and hepatic lipid oxidation.
In the Chinese Phase 3 trials DREAMS-1/2, mazdutide showed superior effects on HbA1c and body weight in type 2 diabetes; the GLORY-1 trial met its primary weight-reduction endpoints in obesity.
Claims circulating online are often not backed by valid clinical data. Treat all information as a starting point for your own scientific research, not as usage guidance.
Sequence and regulatory status data are based on publicly available sources and refer to the compound in general, not to a specific product.
A growing number of preclinical and clinical studies exist for metabolic peptides, though the volume varies significantly by substance.
References without a PMID can be located via the respective publisher. This overview does not claim to be exhaustive.
We reply personally – via email or Telegram.